The present study assessed the cost-effectiveness of atezolizumab versus pembrolizumab for first-line treatment of high PD-L1 (≥ 50%) advanced NSCLC patients in Spain, comparing the results obtained with the interim cut-off (Sept’18) and with the exploratory cut-off (Feb’20) of the IMpower110-study. The gene discussed is CD274; the disease is non-small cell lung carcinoma.